{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-025013","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.648575+00:00","generated_at":"2026-06-13T05:29:58.502870+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lixte Biotechnology announces $3.5M registered direct offering at $6.00/share with warrants","bullets":["Issued 583,334 shares (or equivalents) at $6.00/share plus warrants for 583,334 shares at $6.00, expiring 5 years.","Gross proceeds ~$3.5M; placement agent A.G.P./Alliance Global Partners receives 6.0% fee and warrants at $6.60.","Common stock offered via effective shelf registration S-3 (No. 333-252430); warrants issued in private placement under Section 4(a)(2).","Closing expected July 20, 2023; 90-day lockup on further sales and 180-day prohibition on variable rate transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-025013","json":"https://secwatch.observer/filing/0001493152-23-025013.json","markdown":"https://secwatch.observer/filing/0001493152-23-025013.md","text":"https://secwatch.observer/filing/0001493152-23-025013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/0001493152-23-025013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:29:58.502870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"409b885778d6ddcc752facc7dc45767988d7b1b8","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Securities Purchase Agreement valued at approximately $3,500,000 (effective 2023-07-18).","evidence_excerpt":"On July 18, 2023, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Offering”), 583,334 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof), and common warrants to purchase up to 583,334 shares of common stock in a concurrent private placement, at a purchase price of $6.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/0001493152-23-025013-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Value","value":"approximately $3,500,000"},{"label":"Effective","value":"2023-07-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}